The results of our study demonstrate that the Diopsys® NOVA-VEP can be used to objectively assess the effect of vision rehabilitation therapy in mild TBI patients.
Pine Brook, NJ (PRWEB) November 27, 2013
SUNY Eye Institute, in conjunction with the SUNY College of Optometry, presented two posters on the use of visual evoked potential (VEP) for evaluating traumatic brain injury (TBI) patients at Academy 2013 Seattle, the AAO’s annual meeting. Each study used the Diopsys® NOVA-VEP Vision Testing System to objectively investigate both ocular vision rehabilitation (OVR) and hemifield asymmetries in TBI patients.
The first study researched the effect of ocular vision rehabilitation on VEP amplitude and latency in a mild TBI population having oculomotor dysfunctions. The effect of OVR on visual attention was also analyzed. Researchers found that there was a significant increase in VEP amplitude and decrease in variability after OVR, but no significant change in latency or its variability before or after OVR. Kenneth Ciuffreda, OD, PhD concluded, “The results of our study demonstrate that the Diopsys® NOVA-VEP can be used to objectively assess the effect of vision rehabilitation therapy in mild TBI patients.”
The second study focused on a 36 year-old patient having problems with face recognition following a TBI. Initial results from VEP testing showed a 25% relative amplitude deficit for the right hemifield compared to the left. The patient was then enrolled in an office-based optometric vision therapy and rehabilitation program. After 9 months of therapy, the patient subjectively observed much better facial recognition. “Objective VEP measures showed a reduced amplitude asymmetry between hemifields throughout the therapy, and complete amplitude symmetry was achieved after 17 months,” said Dr. Ciuffreda.
Both studies demonstrate the powerful clinical utility of the Diopsys® NOVA-VEP Vision Testing System in the assessment of patients with traumatic brain injury. However, the Diopsys® NOVA-VEP has also been proven to provide data to aid doctors in the diagnosis of other vision disorders such as glaucoma, amblyopia, retinoblastoma and age-related macular degeneration. To find out more about the Diopsys® NOVA-VEP Vision Testing System, visit http://www.diopsys.com/vep.
Diopsys, Inc. (http://www.diopsys.com) is a medical instrumentation company dedicated to delivering high-quality, cost-effective preventative health care solutions. We specialize in the development and marketing of patient-friendly, non-invasive vision testing equipment utilizing electrophysiology, including Visual Evoked Potential and pattern Electroretinography.
Diopsys developed and markets the patented Diopsys® NOVA-VEP and Diopsys® NOVA-ERG Vision Testing Systems utilized by optometrists and ophthalmologists to help in the detection, diagnosis and treatment of vision disorders, including glaucoma and macular degeneration. Diopsys also provides the Enfant® Pediatric VEP Vision Testing System, a device used in testing for visual deficits, including amblyopia, in children as young as six months of age.